More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$2.36B
EPS
-3.62
P/E ratio
--
Price to sales
26.57
Dividend yield
--
Beta
1.037737
Previous close
$16.86
Today's open
$16.84
Day's range
$16.33 - $17.11
52 week range
$16.33 - $31.74
show more
CEO
Terry Rosen
Employees
601
Headquarters
Hayward, CA
Exchange
New York Stock Exchange
Shares outstanding
143990614
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Arcus Biosciences Reports Third-Quarter 2026 Financial Results and Provides a Pipeline Update
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a pipeline update on its clinical-stage investigational molecules and discovery programs. “In October, we showed for the first time that robust and durable HIF-2.
Business Wire • Nov 4, 2026

Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Lags Revenue Estimates
Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to a loss of $1.27 per share a year ago.
Zacks Investment Research • Nov 5, 2026

Arcus Biosciences to Participate in the Jefferies Global Healthcare Conference 2026 in London
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases, announced that its management team will participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference in London, UK. The fireside chat will take place on Monday, November 16th, 2026, at 5:00pm GMT. A live webcast of the presentation will.
Business Wire • Nov 2, 2026

Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted three new employees options to purchase a total of 10,650 shares of the Company's common stock at an exercise price per share of $18.54, which was the closing price.
Business Wire • Oct 26, 2026

Arcus Biosciences Sees $5B-$10B RCC Opportunity for Casdatifan at Investor Day
Arcus Biosciences NYSE: RCUS presented updated clinical and translational data for casdatifan, its investigational HIF-2 alpha inhibitor, outlining development plans across first-line, second-line and later-line clear cell renal cell carcinoma (RCC).
MarketBeat • Oct 21, 2026

Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm
NEW YORK, Oct. 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Arcus Biosciences, Inc. ( NYSE : RCUS) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
PRNewsWire • Oct 21, 2026

Arcus Biosciences Announces Commencement of Public Offering of Common Stock
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases, today announced that it has commenced an underwritten public offering of its common stock. All of the shares of common stock are being offered by Arcus Biosciences. In addition, Arcus Biosciences intends to grant the underwriters a 30-day option to purchase.
Business Wire • Oct 21, 2026

Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combinations for the treatment of cancer and immune diseases, today announced the pricing of an underwritten public offering of 14,285,715 shares of its common stock at a price to the public of $17.50 per share. Gross proceeds to Arcus Biosciences from the offering are expected to be $250.0 million, before deducting underwriti.
Business Wire • Oct 22, 2026

Arcus Biosciences: Encouraging Casdatifan Data, But The Hard Part Still Ahead
Arcus Biosciences presented promising ARC-20 platform data for casdatifan across first-line, second-line, and late-line clear cell renal cell carcinoma settings. RCUS's casdatifan combinations showed superior or competitive PFS and response rates versus historical benchmarks, with manageable safety profiles and broad potential across treatment lines. Valuation is rich at 22.5x trailing and 37.9x forward sales, reflecting high pipeline expectations and leaving RCUS vulnerable to clinical setbacks.
Seeking Alpha • Oct 21, 2026

Arcus Biosciences, Inc. (RCUS) Discusses New Data on Casdatifan for Kidney Cancer Across Multiple Lines of Therapy Transcript
Arcus Biosciences, Inc. (RCUS) Discusses New Data on Casdatifan for Kidney Cancer Across Multiple Lines of Therapy Transcript
Seeking Alpha • Oct 20, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Arcus Biosciences Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.